Supplementary Figure 1

Gene name	Primer sequence
ABCC1-FW	5’-AGCCGGTGAAGGTTGTGTAC -3’
ABCC1-RV	5’-TGACGAAGCAGATGTGGAAG -3’
ABCG2-FW	5’-GCAGATGCCTTCTTCGTTATG -3’
ABCG2-RV	5’-TCTTCGCCAGTACATGTTGC -3’
AXIN2-FW	5’-CCAGACTCAGTGGGAAGAGC -3’
AXIN2-RV	5’- AAGAGACAGGCATGGGTTTG -3’
BMI1-FW	5’- CCAGGGCTTTTCAAAAATGA -3’
BMI1-RV	5’-CCGATCCAATCTGTTCTGGT -3’
CD44 -FW	5’- GGGATTGGTTTTCATGGTTG -3’
CD44 -RV	5’-GTGTGGTTGAAATGGTGCTG -3’
Gli-1-FW	5’ –GTGCAAGTCAAGCCAGAACA -3’
Gli-1-RV	5’-ATAGGGGCCTGACTGGAGAT -3’
Gli-2-FW	5’-TGGAATTTGGAACTGGCTTC -3’
Gli-2-RV	5’-CCTCATTAAGGCCAAGGTCA -3’
Hes-1-FW	5’-TTCCCTCCGGACTCTAAACA -3’
Hes-1-RV	5’-CAAACATCTTTGGCATCACA -3’
Hes-5-FW	5’- GCCGTTTTAGGACAATCAGG -3’
Hes-5-RV	5’-GAGTTCGGCCTTCACAAAAG -3’
HPRT-FW	5’- TGCTCGAGATGTGATGAAGG -3’
HPRT-RV	5’- TCCCCTGTTGACTGGTCATT -3’
Nanog-FW	5’- CCTCCTCCATGGATCTGCTTATTCA -3’
Nanog-RV	5’-CAGGTCTTCACCTGTTTGTAG -3’
N-Cadherin-FW	5’-GACAATGCCCCTCAAGTGTT -3’
N-Cadherin-RV	5’-CCATTAAGCCGAGTGATGGT -3’
Oct4-FW	5’-CGACCATCTGCCGCTTTGAG-3’
Oct4-RW	5’- CCCCCTGTCCCCCATTCCTA -3’
RPL-FW	5'-TTAAATCCTTGAGGGGTACA-3'
RPL-RV	5'-ACGGGACTTCTAAAAGGAAC-3'
Sox2-FW	5’-CCCCCGGCGGCAATAGCA -3’
Sox2-RV	5’-TCGGCGCCGGGGACATACAT -3’
Twist1-FW	5’-GTCCGCAGTCTTACGAGGAG -3’
Twist1-RV	5’-CCAGCTTGAGGGTCTGAATC -3’
Vimentin-FW	5’-GAGAACTTTGCCGTTGAAGC -3’
Vimentin-RV	5’-TCCAGCAGCTTCCTGTAGGT -3’

Supplementary Figure 1.The sequence of the primers used in the study.

Supplementary Figure 2

shBmi1- Sense:
CCGGAACCAGACCACTACTGAATATCTCGAGATATTCAGTAGTGGTCTG
GTTTTTTTG

shBmi1- Anti Sense:
AATTCAAAAAAACCAGACCACTACTGAATATCTCGAGATATTCAGTAGT
GGTCTGGTT

Supplementary Figure 2. Nucleotide sequence of Bmi1 shRNA used in the study.

Supplementary Figure 3

Sl No.	Tissue No.	Bmi1 intensity
1	BT101	+
2	BT102	+
3	BT103	+
4	BT104	+
5	BT105	+
6	BT106	+
7	BT107	+
8	BT108	+
9	BT109	+
10	BT110	++
11	BT111	++
12	BT112	++
13	BT113	++
14	BT114	++
15	BT115	++
16	BT116	++
17	BT117	++
18	BT118	++
19	BT119	++
20	BT120	++
21	BT121	+++
22	BT122	+++
23	BT123	+++
24	BT124	+++
25	BT125	+++

Supplementary Figure 3. The status of Bmi1 protein levels in 25 primary breast adenocarcinoma samples as analyzed by immunohistochemistry. High: +++, Medium: ++, Low: +.

Supplementary Figure 4



Supplementary Figure 4. Representative images showing morphology of NBLE-LP and MDAMB231 cells with vector alone or upon Bmi1 knockdown.

Supplementary Figure 5

A



	NBLE-LP Vector	NBLE-LP shBmi1
IC_{50}	0.8534	0.4674

B



	MDAMB231-Vector	MDAMB231-shBmi1
IC_{50}	0.8084	0.3955

Supplementary Figure 5. Non-linear regression curve (Curve fit) to calculate IC_{50} value of doxorubicin in NBLE-LP vector and NBLE-LP shBmi1 stable cell lines (A) and MDAMB231-Vector and MDAMB231-shBmi1 stable cell lines (B); n=3, error bars indicate S.D.